Regulatory MSD secures EC clearance for Keytruda combination therapy for ovarian cancer Pharmaceutical TechnologyMSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer.RegulatoryOncologyRead full story pharminent April 6, 2026 (Last updated: April 6, 2026) Pharmaceutical Technology MSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Trump revives pharma tariffs with 100% charges, but leaves loopholesNext: Aspect Biosystems receives funding for cellular medicine project Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
